Scopus BioPharma, Inc. (NASDAQ: SCPS) is a clinical-stage specialty biotechnology company focused on the development and commercialization of novel therapies for rare and serious diseases. Its lead product candidate, CAM2029, is an investigational long-acting somatostatin analog designed for subcutaneous monthly and quarterly dosing in patients with acromegaly and gastroenteropancreatic neuroendocrine tumors. In addition to CAM2029, the company maintains a preclinical pipeline targeting other endocrinology and oncology indications with high unmet medical needs.
Founded in 2018 and headquartered in Wayne, Pennsylvania, Scopus BioPharma was formed through the consolidation of exclusive global rights to CAM2029. Since its inception, the company has entered into strategic partnerships with established contract research and manufacturing organizations across North America and Europe to advance its lead program through Phase 2 clinical studies and to prepare for potential regulatory submissions to the U.S. Food and Drug Administration and the European Medicines Agency.
Scopus BioPharma’s management team is led by Chief Executive Officer James A. Weiss, PhD, who brings over two decades of experience in biotech product development and commercialization. The executive leadership also includes Chief Medical Officer Dr. Laura Chen, formerly of a leading endocrinology research institute, and Chief Financial Officer Michael Torres, CPA, whose background spans both public and private biopharmaceutical companies.
Targeting patient populations in the United States and Europe, Scopus BioPharma aims to address significant gaps in treatment options for endocrine tumors and related disorders. The company’s approach combines specialized formulation technology with a focused clinical development strategy, positioning it to potentially bring differentiated therapies to market for patients with few existing alternatives.
AI Generated. May Contain Errors.
